Chelation therapy is the mainstream treatment for heavy metal poisoning. Apart from this, therapy using antioxidant/herbal extracts are the other strategies now commonly being tried for the treatment. We have previously reported individual beneficial efficacy of nanoparticle mediated administration of an antioxidant like ‘curcumin’ and an arsenic chelator ‘monoisoamyl 2,3-dimercaptosuccinic acid (MiADMSA)’ for the treatment of arsenic toxicity compared to bulk drugs. The present paper investigates our hypothesis that a combination drug delivery therapy employing two nanosystems, a chelator and a strong antioxidant, may produce more pronounced therapeutic effects compared to individual effects in the treatment of arsenic toxicity.

An in-vivo study was conducted wherein arsenic as sodium arsenite (100 ppm) was administered in drinking water for 5 months to Swiss albino mice. This was followed by a treatment protocol comprising of curcumin encapsulated chitosan nanoparticles (nano-curcumin, 15 mg/kg, orally for 1 month) either alone or in combination with MiADMSA encapsulated polymeric nanoparticles (nano-MiADMSA, 50 mg/kg for last 5 days) to evaluate the therapeutic potential of the combination treatment. Our results demonstrated that co-treatment with nano-curcumin and nano-MiADMSA provided beneficial effects in a synergistic way on the adverse changes in oxidative stress parameters and metal status induced by arsenic.

螯合疗法是重金属中毒的主流疗法。除此之外，使用抗氧化剂/草药提取物进行治疗是目前通常尝试的其他治疗方法。以前我们已经报道了纳米粒子介导的抗氧化剂（如“姜黄素”）和砷螯合剂“单异戊基2,3-二巯基琥珀酸（MiADMSA）”的个体有益疗效，与散装药物相比，砷的毒性更高。本文研究了我们的假设，即与两种单独的砷毒性治疗方法相比，采用两种纳米系统，一种螯合剂和一种强抗氧化剂的联合药物递送疗法可能产生更明显的治疗效果。

进行了一项体内研究，其中将砷作为亚砷酸钠（100 ppm）的砷在饮用水中给予瑞士白化病小鼠5个月。随后是包含姜黄素包封的壳聚糖纳米颗粒（纳米姜黄素，15 mg / kg，口服1个月）的治疗方案，该治疗方案可单独使用，也可与MiADMSA包封的聚合物纳米颗粒（nano-MiADMSA，最近5个剂量为50 mg / kg ）组合使用天）以评估联合治疗的治疗潜力。我们的结果表明，纳米姜黄素和纳米MiADMSA的协同处理以协同方式对砷引起的氧化应激参数和金属状态的不利变化产生了有益的影响。